LKFT logo

Lakefront Biotherapeutics (LKFT)

$29.05

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LKFT

Market cap

$1.91B

EPS

5.72

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.257609

Price on LKFT

Previous close

$28.94

Today's open

$28.94

Day's range

$28.69 - $29.23

52 week range

$26.42 - $37.78

Profile about LKFT

CEO

Henry Gosebruch

Employees

704

Headquarters

Mechelen,

Exchange

Nasdaq Global Select

Shares outstanding

65897071

Issue type

American Depository Receipt

LKFT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LKFT

Acquisition of Own Shares

Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 77,667 Lakefront shares between 15 June 2026 and 19 June 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 15/06/2026 EXNT 13,272 24.9331 330,912.10 24.7200 25.2200 16/06/2026 EXNT 16,400 24.5495 402,611.80 24.1200 25.2600 17/06/2026 EXNT 13,605 24.4212 332,250.43 24.0000 24.7800 18/06/2026 EXNT 16,960 24.8036 420,669.06 24.4800 25.1200 19/06/2026 EXNT 17,430 24.5966 428,718.74 24.3600 24.7600 Total   77,667 24.6586   1,915,162.13   24.3360 25.0280 As of market close on 19 June 2026, Lakefront holds 116,204 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

news source

GlobeNewsWire • 21 hours ago

news preview

Lakefront Announces Initiation of €50 Million Stock Repurchase Program

Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC.

news source

GlobeNewsWire • Jun 9, 2026

news preview

Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer

Mechelen, Belgium ; June 8, 2026, 22:01 CET; Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company's strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. 1 Eric will report to Henry Gosebruch, CEO and join the Company's Management Committee.

news source

GlobeNewsWire • Jun 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Lakefront Biotherapeutics

Open an M1 investment account to buy and sell Lakefront Biotherapeutics commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LKFT on M1